Disclosed are lipidoid compounds as well as lipidoid nanoparticles comprising such compounds.

Disclosed are lipidoid compounds as well as lipidoid nanoparticles comprising such compounds.

The present invention provides methods for modulating opioid receptor mediated analgesic effect, e.g., promoting or enhancing analgesia in subjects in need of pain relief. Also provided in the invention are methods for ameliorating or suppressing withdrawal symptoms in subjects with chronic opioid use. These methods of the invention entail administering to the subjects in need of treatment a therapeutically effective amount of a GPR139 antagonist compound. The invention further provides methods for identifying novel compounds that can be useful for modulating opioid receptor mediated analgesic effect.

The present invention provides methods for modulating opioid receptor mediated analgesic effect, e.g., promoting or enhancing analgesia in subjects in need of pain relief. Also provided in the invention are methods for ameliorating or suppressing withdrawal symptoms in subjects with chronic opioid use. These methods of the invention entail administering to the subjects in need of treatment a therapeutically effective amount of a GPR139 antagonist compound. The invention further provides methods for identifying novel compounds that can be useful for modulating opioid receptor mediated analgesic effect.

The subject invention provides compounds as antitoxins for mitigating the toxic effects of algal toxins, e.g., brevetoxins. These compounds are mercaptan based compounds and derivatives that react rapidly with such toxins, e.g., brevetoxins and can be used to treat poisoning in a subject caused by such toxins. The subject invention also provides compositions comprising the mercaptan based compounds and derivatives for use to mitigate the toxic effects of brevetoxins. Further provided are methods of using the mercaptan based compounds and derivatives and compositions for treating and/or preventing brevetoxin poisoning in a subject such a human and marine animal.

The subject invention provides compounds as antitoxins for mitigating the toxic effects of algal toxins, e.g., brevetoxins. These compounds are mercaptan based compounds and derivatives that react rapidly with such toxins, e.g., brevetoxins and can be used to treat poisoning in a subject caused by such toxins. The subject invention also provides compositions comprising the mercaptan based compounds and derivatives for use to mitigate the toxic effects of brevetoxins. Further provided are methods of using the mercaptan based compounds and derivatives and compositions for treating and/or preventing brevetoxin poisoning in a subject such a human and marine animal.

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K.sup.+) channel activator at a dosage effective to restore normal brain interstitial glial K.sup.+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.

Provided herein are, inter alia, methods for treating cancers having KRAS mutations using ITGB4/PXN pathway inhibitors, Wnt/β-catenin pathway inhibitors, KRAS pathway inhibitors, and combinations thereof; and pharmaceutical compositions comprising the ITGB4/PXN pathway inhibitors, Wnt/β-catenin pathway inhibitors, KRAS pathway inhibitors, and combinations thereof.

Provided herein are, inter alia, methods for treating cancers having KRAS mutations using ITGB4/PXN pathway inhibitors, Wnt/β-catenin pathway inhibitors, KRAS pathway inhibitors, and combinations thereof; and pharmaceutical compositions comprising the ITGB4/PXN pathway inhibitors, Wnt/β-catenin pathway inhibitors, KRAS pathway inhibitors, and combinations thereof.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.